← Leaderboards
Mae O Gordon
Washington University
$27,922,592
Attributed
$29,769,936
Total exposure
18
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,769,936 · 18
By mechanism
U10$15,205,699 · 2
UG1$8,290,521 · 2
R21$2,506,777 · 6
R01$1,532,567 · 2
P30$1,236,235 · 4
R34$605,387 · 1
Top collaborators
- Feng Gao6 shared
- Lei Liu4 shared
- John H Fingert3 shared
- Todd E Scheetz3 shared
Most similar at Washington University
Same institution · by research overlap
- Michael A Kass$23,482,010
- Anjali Maruti Bhorade$2,784,300
- Ganesh M Babulal$13,883,355
- Russell N Van Gelder$16,133,253
- Jeffrey Miner$617,964
Others in their field
Top investigators on “Visual Fields”
- Hongkui Zeng · Allen Institute$73,890,312
- Curtis L Meinert · Johns Hopkins University$72,267,482
- Rohit Varma · University Of Southern California$43,073,348
- Ed Lein · Allen Institute$39,833,496
- Dennis L Matthews · University Of California-Davis$39,323,652
- Walter A Kukull · University Of Washington$37,052,427
Research focus
Visual FieldsOcular HypertensionHypertension TreatmentParticipantVisionPrimary Open Angle GlaucomaPublicationsReportingProtocols DocumentationGlaucomaOptic DiskResearch PersonnelUniversitiesWashingtonFollow-UpResourcesCohort StudiesBiometryRisk FactorsGrantBlindnessFundingPreparationCost
Grant awards (64)
Genetic Factors for Glaucoma in the OHTS; Risk, Progression and Mechanism$400,478
R01 · FY2025 · EY
Genetic Factors for Glaucoma in the OHTS; Risk, Progression and Mechanism$400,478
R01 · FY2024 · EY
Long-Term Quality of Life in the Ocular Hypertension Treatment Study Cohort$198,322
R21 · FY2024 · EY · contact PI
Biostatistics and Bioinformatics core$84,294
P30 · FY2024 · EY · contact PI
Genetic Factors for Glaucoma in the OHTS; Risk, Progression and Mechanism$414,353
R01 · FY2023 · EY
Long-Term Quality of Life in the Ocular Hypertension Treatment Study Cohort$246,254
R21 · FY2023 · EY · contact PI
Resubmission: Latent Class Trajectory Analysis in the OHTS Study$233,250
R21 · FY2023 · EY
Biostatistics and Bioinformatics core$84,294
P30 · FY2023 · EY · contact PI
Resubmission: Latent Class Trajectory Analysis in the OHTS Study$196,458
R21 · FY2022 · EY
Biostatistics and Bioinformatics core$98,661
P30 · FY2022 · EY · contact PI
Innovative Analytical Methods for Repeated Measures in the OHTS Study$235,936
R21 · FY2021 · EY
Biostatistics and Bioinformatics core$98,661
P30 · FY2021 · EY · contact PI
AT-RISK DRIVING AND COMPENSATORY STRATEGIES IN OLDER ADULTS WITH GLAUCOMA$317,258
R01 · FY2020 · EY · contact PI
Innovative Analytical Methods for Repeated Measures in the OHTS Study$203,498
R21 · FY2020 · EY
Reducing Adeno-Viral Patient Infected Days: Secondary Analyses$196,875
R21 · FY2020 · EY · contact PI
Biostatistics and Bioinformatics core$98,661
P30 · FY2020 · EY · contact PI
Ocular Hypertension Treatment Study 20-Year Follow-up: Coordinating Center Grant$1,189,459
UG1 · FY2019 · EY · contact PI
Reducing Adeno-Viral Patient Infected Days: Secondary Analyses$235,625
R21 · FY2019 · EY · contact PI
Biostatistics Module$40,762
P30 · FY2019 · EY · contact PI
Ocular Hypertension Treatment Study 20-Year Follow-up: Clinical Center Grant$11,097
UG1 · FY2019 · EY · contact PI
Ocular Hypertension Treatment Study 20-Year Follow-up: Coordinating Center Grant$960,279
UG1 · FY2018 · EY · contact PI
Biostatistics Module$40,762
P30 · FY2018 · EY · contact PI
Ocular Hypertension Treatment Study 20-Year Follow-up: Clinical Center Grant$1
UG1 · FY2018 · EY · contact PI
Ocular Hypertension Treatment Study 20-Year Follow-up: Clinical Center Grant$923,725
UG1 · FY2017 · EY · contact PI
Ocular Hypertension Treatment Study 20-Year Follow-up: Coordinating Center Grant$840,057
UG1 · FY2017 · EY · contact PI
REDUCING ADENOVIRAL PATIENT-INFECTED DAYS (RAPID)$147,887
R34 · FY2017 · EY · contact PI
Biostatistics Module$40,762
P30 · FY2017 · EY · contact PI
Ocular Hypertension Treatment Study 20-Year Follow-up: Clinical Center Grant$1,097,707
UG1 · FY2016 · EY · contact PI
Ocular Hypertension Treatment Study 20-Year Follow-up: Coordinating Center Grant$933,477
UG1 · FY2016 · EY · contact PI
REDUCING ADENOVIRAL PATIENT-INFECTED DAYS (RAPID)$228,750
R34 · FY2016 · EY · contact PI
Biostatistics Module$40,762
P30 · FY2016 · EY · contact PI
Ocular Hypertension Treatment Study 20-Year Follow-up: Clinical Center Grant$1,353,969
UG1 · FY2015 · EY · contact PI
Ocular Hypertension Treatment Study 20-Year Follow-up: Coordinating Center Grant$980,750
UG1 · FY2015 · EY · contact PI
REDUCING ADENOVIRAL PATIENT-INFECTED DAYS (RAPID)$228,750
R34 · FY2015 · EY · contact PI
Biostatistics Module$40,762
P30 · FY2015 · EY · contact PI
FACTORS PREDICTIVE OF RAPID VISUAL FIELD LOSS IN EARLY GLAUCOMA$191,540
R21 · FY2014 · EY
FACTORS PREDICTIVE OF RAPID VISUAL FIELD LOSS IN EARLY GLAUCOMA$195,449
R21 · FY2013 · EY
FOLLOW-UP INTRAOCULAR PRESSURE AND THE RISK OF DEVELOPING PRIMARY OPEN-ANGLE GLAU$181,138
R21 · FY2010 · EY
Ocular Hypertension Treatment Study: Coordinating Center$1,301,816
U10 · FY2009 · EY · contact PI
FOLLOW-UP INTRAOCULAR PRESSURE AND THE RISK OF DEVELOPING PRIMARY OPEN-ANGLE GLAU$192,432
R21 · FY2009 · EY
CORE--BIOSTATISTICS$67,511
P30 · FY2009 · EY · contact PI
Ocular Hypertension Treatment Study: Coordinating Center$1,301,816
U10 · FY2008 · EY · contact PI
CORE--BIOSTATISTICS$65,620
P30 · FY2008 · EY · contact PI
Ocular Hypertension Treatment Study: Coordinating Center$1,263,904
U10 · FY2007 · EY · contact PI
CORE--BIOSTATISTICS$63,783
P30 · FY2007 · EY · contact PI
Ocular Hypertension Treatment Study: Coordinating Center$1,234,516
U10 · FY2006 · EY · contact PI
CORE--BIOSTATISTICS$54,777
P30 · FY2006 · EY · contact PI
Ocular Hypertension Treatment Study: Coordinating Center$1,198,559
U10 · FY2005 · EY
EGPS/OHTS Collaborative Analysis$189,750
R03 · FY2005 · EY
CORE--BIOSTATISTICS$53,249
P30 · FY2005 · EY
Ocular Hypertension Treatment Study: Coordinating Center$1,387,679
U10 · FY2004 · EY
CLEK-COORDINATING CENTER$343,682
U10 · FY2004 · EY
EGPS/OHTS Collaborative Analysis$203,000
R03 · FY2004 · EY
OHTS COORDINATING CENTER$1,327,839
U10 · FY2003 · EY
CLEK-COORDINATING CENTER$682,561
U10 · FY2003 · EY
OHTS COORDINATING CENTER$1,287,998
U10 · FY2002 · EY
CLEK-COORDINATING CENTER$671,538
U10 · FY2002 · EY
CORE--BIOSTATISTICS$87,638
P30 · FY2002 · EY
OHTS COORDINATING CENTER$1,017,499
U10 · FY2001 · EY
CLEK--DATA COORDINATING CENTER$643,383
U10 · FY2001 · EY
CORE--BIOSTATISTICS$87,638
P30 · FY2001 · EY
OHTS COORDINATING CENTER$938,435
U10 · FY2000 · EY
CLEK--DATA COORDINATING CENTER$604,474
U10 · FY2000 · EY
CORE--BIOSTATISTICS$87,638
P30 · FY2000 · EY